Streetbeat News

Revenues

NTRA

Natera, Inc. (NASDAQ:NTRA) reported preliminary Q4 revenue of $300M, surpassing estimates of $276.02M and marking a 38% increase YoY. Full-year revenue for 2023 is expected to be $1.07B, exceeding the $1.05B estimate and showing a 30% growth from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:13 pm

MCRB

Seres Therapeutics reported preliminary unaudited net sales of $10.4M for Q4 2023, with total net sales of $19.6M since the June 2023 launch of Vowst. The sales figures reflect a gross-to-net reduction of 13%. The company saw significant adoption of Vowst, with 2,833 patient enrollment forms received and 2,015 new patient starts by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:11 pm

CDNA

CareDx, Inc. has announced its preliminary revenue for Q4 to be between $65M-$66M, which represents a decrease of about 3% from the previous quarter. This figure surpasses the estimated revenue of $61.71M. The company also reported that its preliminary cash, cash equivalents, and marketable securities were approximately $235 million as of December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:11 pm

GKOS

Glaukos Corporation has reaffirmed its fiscal year 2024 net sales guidance, projecting a range of $350 million to $360 million. This forecast aligns closely with the consensus estimate of $354.59 million by analysts.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:09 pm

CDNA

CareDx expects its full-year 2023 revenue to be between $279M-$280M, surpassing the high end of its guidance and analysts' estimate of $276.43M. However, this represents a 13% decrease from the 2022 revenue of $321.8M, mainly due to the impact of the Medicare Billing Article on Testing Services revenue.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:08 pm

GKOS

Glaukos Corporation reported preliminary Q4 FY23 net sales exceeding $81M and over $313M for the full year FY23, surpassing consensus estimates of $76.69M for Q4 and $309.05M for the full year.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:08 pm

VNT

Vontier Corporation has sold its Coats business to Victor Capital Partners for $72.5 million in an all-cash deal. Coats is expected to generate $110 million in revenue and $10 million in EBITDA for 2023. The financial results of Coats are included in Vontier's 'Other' segment and will be removed from continuing operations from the transaction's completion date, January 8, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:05 pm

F

RIVN

TSLA

Tesla Inc.'s (NASDAQ:TSLA) price cuts in 2023 have significantly reduced the price gap between electric vehicles (EVs) and internal combustion engine (ICE) vehicles. Cox Automotive reports that by December, the average Tesla vehicle price was $50,051, close to the average ICE vehicle price of $48,759. The average EV price also dropped to $50,798. High inventory levels for EVs were reported, but Tesla and Rivian Automotive Inc. (NASDAQ:RIVN) were excluded from this data. The University of Exeter suggests EVs may become more affordable than gas vehicles in the U.S. this year. Ford Motor Co (NYSE:F) paused its $12 billion EV funding due to high EV costs and customer reluctance.

Portfolio Pulse from Ramakrishnan M

January 09, 2024 | 12:04 pm

EA

In the past three months, 7 analysts have provided ratings for Electronic Arts (NASDAQ:EA), with recent shifts in sentiment. The average 12-month price target is now $150.57, up 6.79% from the previous $141.00. Analysts from BMO Capital, Deutsche Bank, Roth MKM, JP Morgan, Wedbush, and Wells Fargo have adjusted their ratings and price targets, reflecting a positive outlook on EA's performance. EA's financials show a market cap above industry average, a revenue growth rate of 0.53%, a net margin of 20.85%, ROE of 5.35%, ROA of 3.04%, and a low debt-to-equity ratio of 0.26.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 12:01 pm

ALHC

Alignment Healthcare (NASDAQ:ALHC) has received mixed analyst ratings over the past three months, with 2 bullish and 3 indifferent ratings. The average 12-month price target is $9.45, up 11.18% from the previous $8.50. Analysts from Raymond James, UBS, B of A Securities, and Stephens & Co. have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown a revenue growth of 26.74% as of September 30, 2023, but struggles with profitability and debt management, having a net margin of -7.67% and a debt-to-equity ratio of 0.91.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 12:01 pm